Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

U.S. researchers said Wednesday they have reproduced the pain-relieving effects of cannabis with a synthesized compound that ...

The U.S. Food and Drug Administration recently approved a new class of non-opioid painkiller which one Lowcountry pharmacist is calling “revolutionary.” ...

Here's why four Motley Fool contributors think chip giants Nvidia ( NVDA -0.26%) and Micron Technologies ( MU -1.05%), travel ...